Accelerate Diagnostics Schedules Call to Review 3rd Quarter 2021 Results

Rhea-AI Summary

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced a conference call on November 9, 2021, at 4:30 PM ET to discuss its third-quarter financial results for 2021. The call will review financial performance and operational updates, providing insights to investors and stakeholders. For audio webcasting, participants can visit ir.axdx.com. A replay will be available until February 9, 2022. The company focuses on combating antibiotic resistance and sepsis with its cutting-edge Accelerate Pheno® system.

Positive

• Upcoming conference call on November 9, 2021, for Q3 results.
• Company focuses on critical healthcare solutions, notably antibiotic resistance and sepsis.

Negative

• None.

TUCSON, Ariz., Oct. 19, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Tuesday, November 9, 2021, at 4:30 p.m. Eastern Time to review 2021 third quarter financial results.

To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available until February 9, 2022.

To listen by phone, dial +1.877.883.0383 and enter the conference ID: 7399350.  International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference.

A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (international) using the replay code 10160827 until November 30, 2021.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for serious infections. The FDA-cleared system and kit fully automate sample preparation steps, enabling phenotypic antibiotic susceptibility results in about 7 hours directly from positive blood cultures. Recent external studies indicate the solution offers results 1 to 2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient's infection, days earlier.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

Media Contact:
Laura Pierson
lpierson@axdx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-schedules-call-to-review-3rd-quarter-2021-results-301402711.html

SOURCE Accelerate Diagnostics, Inc.

FAQ

What is the date of the Accelerate Diagnostics conference call for Q3 2021 results?

The conference call is scheduled for November 9, 2021.

How can I listen to the Accelerate Diagnostics Q3 results call?

You can listen via audio webcast at ir.axdx.com.

What time will the Accelerate Diagnostics Q3 conference call start?

The call will start at 4:30 PM Eastern Time.

What is the ticker symbol for Accelerate Diagnostics?

The ticker symbol for Accelerate Diagnostics is AXDX.

When will the replay of the Accelerate Diagnostics call be available until?

The replay will be available until February 9, 2022.